BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Centrum Broking Report
PI Industries Ltd. announced multiple acquisitions to foray into pharma space. The company had raised Rs 20 billion in July 2020 to foray into pharma space through inorganic route.
Later in July 2021, PI Industries entered into SPA to acquire Ind-Swift Laboratories’ active pharma ingredient business on a slump sale basis.
However, by November 2021, the deal was called off by Ind-Swift Laboratories. Since then, PI Industries has been scouting for pharma assets.
Yesterday’s announcement puts PI Industries’ long impending pharma foray initiative to rest.
We believe this is a landmark development for PI and shall continue to benefit custom synthesis manufacturing growth over the next foreseeable future.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
How Not To Be Broke In Your Early 20s
May 31, 2024
Orchid Pharma Q4 Results Review - Foray Into Branded Formulations: Systematix
May 28, 2024
Sun Pharma Q4 Results Review - Stepping Up Specialty Investments In FY25: Prabhudas Lilladher
May 23, 2024
Why Quadria Capital’s Amit Varma Is Bullish On The Pharma Sector
May 16, 2024
POPULAR